Norwood, MA - October 1, 2014 - Corbus Pharmaceuticals Holdings, Inc., an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab™, for the treatment of rare, life-threatening inflammatory diseases, announced today that the Company's Chief Executive Officer, Yuval Cohen, Ph.D., will be presenting at the 13th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual BIO Investor Forum features emerging private and public companies. The meeting will be held October 7-8, 2014 at the Palace Hotel in San Francisco, California.

Dr. Cohen will present on Wednesday October 8, 2014, at 9:30 a.m. Pacific Time (12:30 a.m. Eastern Time) in the Marina Room at the Palace Hotel. The presentation will include a Company update and a review of the clinical development plans for Resunab in the treatment of Systemic Sclerosis and Cystic Fibrosis.

Dr. Cohen and the Company's Chief Financial Officer, Sean Moran, will be available to participate in one-on-one meetings with investors and attendees of the conference. Meetings with Corbus Pharmaceuticals may be scheduled through BIO's One-on-One Partnering™ system.

About The BIO Investor Forum

The 13th Annual BIO Investor Forum is an international investor conference focused on private and emerging public biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and established biotechnology companies.

About Resunab™

Resunab is a novel synthetic oral drug with unique anti-inflammatory and anti-fibrotic activity. Pre-clinical and Phase 1 studies have shown Resunab to have an excellent safety profile in humans and promising potency. Resunab binds to the CB2 receptor of immune cells and triggers a process known as "inflammatory resolution", in effect turning chronic inflammation "off."

About Corbus Pharmaceuticals

Corbus Pharmaceuticals is a clinical stage biopharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare ("orphan"), life-threatening inflammatory-fibrotic diseases with clear unmet medical needs. Our lead product Resunab is a novel oral anti-inflammatory drug scheduled to commence Phase 2a clinical trials for the treatment of cystic fibrosis and diffuse scleroderma in 2015. For more information, please visit www.CorbusPharma.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from studies and clinical trials involving Resunab or other product candidates. Corbus Pharmaceuticals Holdings, Inc. also faces risks related to its ability to enroll patients in studies and may need to modify or delay these studies. As a result, Resunab may never be successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. All forward-looking statements are based on information currently available to Corbus Pharmaceuticals Holdings, Inc. and the Company assumes no obligation to update any such forward-looking statements.

Investor and Media Contact:

Jenene Thomas
Investor Relations and Corporate Communications Advisor
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
Email: Jenene@jenenethomascommunications.com

Released October 1, 2014